Hub Tenant

NemaLife

Whole-life studies with C. elegans are traditionally performed on agar-plates. This approach is time consuming due to animal transfers and manual scoring of animal response, and therefore, does not scale favorably for high throughput screening. At NemaLife, we have developed the world's first benchtop screening system that overcomes current challenges in conducting large-scale in vivo assays for applications in genetic and drug screens, toxicology, and mechanistic studies.

Founder - Siva & Nicki Vanapalli
nicki.vanapalli@nemalifeinc.com